Clinuvel

blackm3

Well-known member
Would it be fair to say an Xp patient requires 1 implant per month (12 per year) ?

My single brain cell tells me there is 5000 Xp patients in Japan only .

If 50% of Japanese Xp patients = 2500 times 12 implants at $22,000Aud is equal to
$660 million in profit per year ?
Ok time for bed 😂
 

macgyver

Well-known member
@investek Looks like a July finish, have they given themselves 7 months leeway for wiggle room (or extra time to analyse results?). 6 patients only as mentioned when the CUV150 trial was first announced. They were expanding the program to include XP-V patients but not in this location by the looks of it.

And one of the participants is 65 years or older? Quite an achievement for someone living with XP.
 
Last edited:

macgyver

Well-known member
@blackm3 Even at 6 implants a year for 2500 Japanese XP patients the potential revenue is staggering. Something we’re not used to that’s for sure 😆
 
Last edited:

endymion96

2nd Longest Active Member
@endymion96 Excellent post Endy. Your insight, especially from someone who has experienced the drug first hand, is especially valuable. Here's a thought given afamelanotide's anti inflammatory benefits - will patients receiving the drug on regular intervals, say 4 to 6 times a year, end up being "healthier" than the general public. Since many diseases have an inflammatory element to them would the regular intake of afamelanotide into their system over an extended period of time prevent many diseases from ever occurring?

One benefit of maintaining the strict patient registries over a period of years may be to see if this hypothesis could be proven.
I tend to think it could help and had originally included a paragraph about this in my reply ... but deleted it as I could not back it up with a scientific study on the matter. But I truly believe so. I think it could prevent CVD and stroke if taken as a prophylactic or at least prolong the time to serious illness. People would still need to mind their health in order to avoid obesity, bad eating habits, and an unhealthy lifestyle. I do not think this drug could cure all issues if the patient is actively working against it. But it could theoretically aid those willing to work in concert with it. This is just an educated guess on my part at this time. Additionally, I think it could be thought of, marketed, and used in the area of anti-aging as a life-extension mechanism.
 

macgyver

Well-known member
@endymion96 I started taking MT2 a few weeks back as an experiment, ideally as a prophylactic to manage inflammation, neuroprotection and atherosclerosis. One thing that really surprised me was: why isn’t this peptide used for obesity? The first time I had it I had one coffee for breakfast and didn’t eat the whole day🤣 Missed lunch, picked at dinner, finally decided I must eat properly and had a midnight snack, more than 24 hours after taking MT2!💀
 
Last edited:

gerritbakker57

Well-known member
Would it be fair to say an Xp patient requires 1 implant per month (12 per year) ?

My single brain cell tells me there is 5000 Xp patients in Japan only .

If 50% of Japanese Xp patients = 2500 times 12 implants at $22,000Aud is equal to
$660 million in profit per year ?
Ok time for bed 😂
And the only thing that happens to the share price is going down down down. I suppose no one, besides us, the ST community, knows the real potential of this drug. I take a nice whisky and watch the footballgame of France against Germany 🥃
 

Sherlock

Well-known member
"Kritiek op nieuw alzheimermedicijn zwelt aan: 'Dit moet je niet voorschrijven' -" https://nos.nl/l/2385189
Some discussion on the alzheimer medicine from biogen of a few days ago: Dutch neurologists hope ema does a better job than fda as they will not prescribe the medicine due to little to no effect and a lot of risk for brain damage. It's giving false hope as they say.
 
Last edited:

Justinian

Well-known member
@endymion96 I started taking MT2 a few weeks back as an experiment, ideally as a prophylactic to manage inflammation, neuroprotection and atherosclerosis. One thing that really surprised me was: why isn’t this peptide used for obesity? The first time I had it I had one coffee for breakfast and didn’t eat the whole day🤣 Missed lunch, picked at dinner, finally decided I must eat properly and had a midnight snack, more than 24 hours after taking MT2!💀

You may already be aware, but MC4R is tied to obesity. MT2 binds more to MC4R than MT1 (Afamelanotide/Scenesse) does.
 

CUV Quote (Yesterday's close)

Time: 4:10PM AEDT
Price: 39.19
Volume: 69444
Top